Minimal residual disease: a key determinant of ALL treatment response
What’s next for rare myelomas?
Which techniques to use to assess disease response in multiple myeloma
Carlos Fernandez de Larrea
Getting specific with myeloma therapy: selecting the right treatments
Managing challenging patients with Waldenström’s macroglobulinemia